Patrick Lin - 31 Jan 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Signature
/s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
31 Jan 2024
Net transactions value
+$9,525
Form type
4
Filing time
01 Feb 2024, 18:32:03 UTC
Previous filing
12 Apr 2024
Next filing
02 Aug 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Purchase $5,925 +2,500 +11% $2.37 25,978 31 Jan 2024 Direct F1
transaction PCSA Common Stock Purchase $3,600 +1,500 +5.8% $2.40 27,478 01 Feb 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.